Fluoroquinolones

01/01/2007 - "Fluoroquinolones are broad-spectrum antimicrobials highly effective in the treatment of a wide variety of clinical infections. "
05/01/2005 - "Fluoroquinolones are broad-spectrum antimicrobials highly effective for treatment of a variety of clinical and veterinary infections. "
01/01/1999 - "When the causative pathogens are susceptible, the fluoroquinolones have been demonstrated to be highly efficacious in the treatment of both mild uncomplicated skin and skin structure infections as well as the more severe complicated infections involving these tissues, including infections of the feet of diabetic patients. "
08/01/2004 - "The Chilean situation triggers important concerns because it includes the use of fluoroquinolones in aquaculture, that are not biodegradable and are able to remain in the environment for years as well as being still effective in treating human infections. "
01/01/2021 - "In contrast, in the treated group, there was no significant difference in the proportion of fluoroquinolone resistance between the infections that persisted and cleared. "

01/01/2019 - "The health care-associated pneumonia intervention resulted in a continued significant reduction in fluoroquinolone use (rate ratio = 0.68, P < .01). "
03/01/1993 - "The fluoroquinolones are effective in treating pneumonia because of their broad spectra of activity against gram-negative and gram-positive organisms, including Streptococcus pneumoniae and Haemophilus influenzae. "
05/22/2000 - "New fluoroquinolones with improved activity against S pneumoniae can also be used to treat adults with community-acquired pneumonia. "
07/01/2008 - "pneumoniae with additional mechanisms of resistance causes decreased efficacy of fluoroquinolones in a pneumonia model in mice."
10/01/2006 - "Guidelines advocate using fluoroquinolones as first-line treatment for community-acquired pneumonia (CAP). "

04/01/2012 - "The advent of this resistance mechanism involves a more rational use of fluoroquinolones, especially as first-line treatment of urinary tract infections."
05/01/2022 - "This study sought to determine whether there is a correlation between MIC and outcomes in those receiving fluoroquinolones (FQs) for urinary tract infections (UTIs) caused by Enterobacterales pathogens. "
01/01/2022 - "This study aims to systematically review the impact of urinary tract infection-targeted ASP on overall AMR, antimicrobial use, and specific to fluoroquinolone (FQ) use in nursing homes (NHs). "
01/01/2021 - "Historically, uncomplicated urinary tract infections have high rates of guideline-discordant treatment with past studies noting substantial use of fluoroquinolones, directly contradicting clinical practice guidelines. "
01/01/2018 - "The aims of this study were (i) to determine the frequency of plasmid-mediated resistance to fluoroquinolones (FQs) in Escherichia coli isolated from patients with urinary tract infections (UTIs) of nosocomial and community origin and (ii) to determine the relationships between the presence of extended-spectrum β-lactamases (ESBLs), mutations in the gyrA and parC genes, and resistance to FQs. "

08/01/2019 - "The rate of fluoroquinolone-susceptible Pseudomonas aeruginosa isolated from urinary tract and respiratory tract infections improved during the period examined from 41.8-67.0% to 91.2-94.2%, and from 78.9-88.5% to 90.1-94.6%, respectively. "
04/01/2003 - "The results from this pharmacodynamic study suggest that these fluoroquinolones would have prolonged killing activity against these organisms in vivo and may have clinical utility in the treatment of mixed aerobic-anaerobic respiratory tract infections."
01/01/2023 - "Generally, there is a viral upper respiratory tract infection or systemic fluoroquinolone usage before BAIT. "
10/01/2018 - "The prevalence of fluoroquinolone prescribing for the treatment of respiratory tract infections (RTIs) appeared to fall with time in all countries and for UTI in France and UK only. "
01/01/2017 - "Although results are variable, the use of fluoroquinolones in patients with respiratory infections seems to delay the diagnosis of TB by nearly two weeks. "

07/01/2013 - "In murine tuberculosis, M had superior efficacy compared with L despite lower serum drug exposures and may remain the fluoroquinolone of choice for second-line regimens. "
01/01/2005 - "The antituberculous efficacy of the new fluoroquinolone agent moxyfloxacin was studied on a model of generalized murine tuberculosis caused by a multidrug-resistant Mycobacterium strain. "
04/01/1998 - "Fluoroquinolones: a new treatment for tuberculosis?"
01/01/2019 - "Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations."
11/01/2016 - "Improved survival in patients with severe tuberculosis after exposure to fluoroquinolones."